GLP-1 RA monotherapy reports showed a statistically significant increase in thyroid hyperplasia and neoplasm AEs, with the ROR being 22.02 (95% CI 10.36-46.84) when compared to SGLT-2 inhibitors. Here, SLC5A2 is linked to neoplasm.